Clinical Trial Update: Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating immunogenicity and safety of a booster dose of a quadrivalent meningococcal conjugate vaccine in children.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• Quadrivalent meningococcal conjugate vaccine (meningococcal conjugate vaccine quadrivalent (MenACWY))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2020-06-05